Coeliac disease

EQS-News: Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Cleveland Clinic, Short course immune induction therapy, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Pharmaceutical industry, Pharmacovigilance

NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:

Key Points: 
  • NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:
    October 11-13: MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting.
  • The poster presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Cleveland Clinic, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Vaccine, Pharmacovigilance, Short course immune induction therapy

The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • The presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

TODAY's Dylan Dreyer Joins Forces with Beyond Celiac to Drive Celiac Disease Awareness and Research

Retrieved on: 
Tuesday, September 26, 2023
Partnership, Face, NBC News, Policy, Coeliac disease, Fear, Alcoa Presents: One Step Beyond, Quality of life, Hope, Research, Celiac, Dentistry

Celiac disease, an autoimmune disorder triggered by the ingestion of gluten, affects an estimated 1 in 133 Americans, making it one of the most common genetic conditions in the world.

Key Points: 
  • Celiac disease, an autoimmune disorder triggered by the ingestion of gluten, affects an estimated 1 in 133 Americans, making it one of the most common genetic conditions in the world.
  • "I am thrilled to be joining forces with Beyond Celiac to make a difference in the lives of those living with celiac disease," said Dreyer.
  • Beyond Celiac is a leading advocate for the celiac disease community, dedicated to improving the quality of life for those living with the condition.
  • Their initiatives focus on driving research, advocating for policy changes, and promoting public awareness of celiac disease.

10-Year-Old Celiac Activist Files Citizen Petition with the FDA to Label Gluten as a Major Food Allergen

Retrieved on: 
Wednesday, September 13, 2023
FDA, Packaging, Retail, Diabetes, Health, Manufacturing, Congressional News, Views, Public Policy, Government, White House, Federal Government, Fitness & Nutrition, Other Manufacturing, State, Local, Food, Beverage, Pillar, FDA citizen petition, Nutrition, Gluten-free diet, Prevalence, Office of Inspector General, U.S. Department of Health and Human Services, Food industry, Food Allergen Labeling and Consumer Protection Act, Public, Food safety, Fear, Eating, Hope, The Honourable, Medicine, Federal, Committee, Consumer Protection Act, Food and Agriculture Organization, White House conference, Integration, Physician, Veterans' affairs, Risk assessment, United, U.S. Department of Veterans Affairs, Office of Inspector General, Coeliac disease, Initiative, Food security, Research, Support, Conference, Generic drug, Flour, Dietary supplement, Gluten, Wheat, Hunger, Oat, Celiac

In honor of National Celiac Awareness Day and the upcoming first anniversary of the White House Conference on Hunger, Nutrition, and Health, Jax Bari, age 10, has filed a Citizen Petition with the FDA to label Gluten as a Major Food Allergen.

Key Points: 
  • In honor of National Celiac Awareness Day and the upcoming first anniversary of the White House Conference on Hunger, Nutrition, and Health, Jax Bari, age 10, has filed a Citizen Petition with the FDA to label Gluten as a Major Food Allergen.
  • Celiac Journey’s Citizen Petition is requesting a long-overdue reckoning by the FDA to better protect more than 3.3 million Americans with Celiac Disease by labeling Gluten (Wheat, Barley, Rye and Oats) as a Major Food Allergen on all packaged foods in the U.S., just like labeling Gluten is done in more than 85 other countries.
  • The Citizen Petition is actionable now under the FDA’s existing authority in the Food Allergen Labeling and Consumer Protection Act (21 U.S.C.
  • Celiac Journey is requesting that the FDA issue a rule to require that all ingredients with Gluten be declared on food labels.

Anokion Announces Clinical Progress with KAN-101 and ANK-700

Retrieved on: 
Tuesday, September 12, 2023
Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Demyelinating disease, Myelin, Safety, Spinal cord, Clinical trial, SAD, Brain, Multiple sclerosis, CNS, MS, Incidence, RRMS, Patient, Autoimmune disease, Immune tolerance, Immune system, Assessment, MAD, Liver, Coeliac disease, Neuroinflammation, Vaccine, Pharmaceutical industry

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700.
  • Anokion has designed ANK-700 to re-educate the immune system by inducing antigen-specific tolerance to myelin-based autoantigens to reduce neuroinflammation in the brain and spinal cord.
  • The study will continue with a 12-month safety follow-up expected to complete in the first half of 2024.
  • Anokion anticipates reporting full results from its MoveS-it clinical trial in the second half of 2024.

ModifyHealth Announces Four New 'Food as Medicine' Meal Plans to Help Fight Costly, Chronic Conditions

Retrieved on: 
Wednesday, August 23, 2023
Food, Hypercholesterolemia, Type 2 diabetes, General Wells, Monash University, Cardiovascular disease, Medicine, Patient, PCOS, Coeliac disease, Diet (assembly), Dietary supplement, Pharmaceutical industry, Hypertension

ATLANTA, Aug. 23, 2023 /PRNewswire/ -- ModifyHealth™, a nationwide leader in the food as medicine space, announces the launch of four new meal plan offerings that target common dietary concerns nationwide: Heart Health, Gluten-Free, Carb Conscious, and Diabetes Friendly. Building upon the success of their Monash University Low-FODMAP Certified™ and Mediterranean diet plans, these new plans provide accessible, convenient meal delivery options for even more Americans requiring dietary modification due to medical concerns, including Celiac Disease, Type 2 Diabetes, High Blood Pressure, PCOS, and more.

Key Points: 
  • Building upon the success of their Monash University Low-FODMAP Certified™ and Mediterranean diet plans, these new plans provide accessible, convenient meal delivery options for even more Americans requiring dietary modification due to medical concerns, including Celiac Disease, Type 2 Diabetes, High Blood Pressure, PCOS, and more.
  • "The expansion of ModifyHealth's meal plans allows us to provide care and relieve pain points for even more consumers dealing with the struggles of restrictive diets," says GB Pratt, Founder & CEO of ModifyHealth.
  • "We look forward to introducing new audiences to the benefits of food as medicine so they can live better and reduce the costs associated with these chronic conditions."
  • ModifyHealth's recipes have been developed by award-winning chefs under the direction of the brand's team of expert, registered dietitians to ensure the meals taste just as good as they are for your body.

Over One-Fourth (28%) of Americans Assume that People Who Eat Gluten-Free Are Just Trying to Get Attention

Retrieved on: 
Wednesday, July 12, 2023
Lymphoma, Life, Coeliac disease, Fear, Cancer, Infertility, Attention, Research, The Harris Poll, Social stigma, Autoimmune disease, Disease, Flour, Dentistry

PHILADELPHIA, July 12, 2023 /PRNewswire/ -- Americans' attitudes toward and understanding of celiac disease fall short, according to a nationwide survey conducted online among 2,081 U.S. adults April 11-13, 2023, by The Harris Poll on behalf of Beyond Celiac, the leading catalyst for a celiac disease cure. The survey found that 28% of Americans assume that people who eat gluten-free are just trying to get attention. However, gluten is dangerous for people with this serious autoimmune disease and following a strict gluten-free diet is the only way the 3.2 million Americans (1 in 133)1 with celiac disease can control it today.

Key Points: 
  • The survey found that 28% of Americans assume that people who eat gluten-free are just trying to get attention.
  • Only 43% of Americans think that going to parties and other kinds of socializing are difficult when you are limited to gluten-free food.
  • Though numerous possible treatments are under investigation , currently there are no medications to treat celiac disease and there is no cure.
  • The full report on the survey results, "The Persisting Myths About Celiac Disease" can be found at https://www.beyondceliac.org/harrispoll/ .

Global Smart Pills Technology Market Report 2023: Sector is Expected to Reach $7,500 Billion by 2030 at a CAGR of 8.8% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 11, 2023
Biotechnology, Technology, IOT (Internet of Things), Diabetes, Health, Oncology, Health Technology, Medical Devices, Infectious Diseases, Artificial Intelligence, Hardware, Systems Failure, Communication, Crohn's disease, Prevalence, Hospice, Capsule endoscopy, Cancer, MEA, Tisbury Great Pond Target Area, Endoscopy, USD, SPES, Tablet, Incidence, Nursing, Esophageal motility disorder, Stomach, Miniaturization, Application, Gastrointestinal bleeding, Plant growth analysis, Conditional sentence, Diagnosis, Growth, Hospital, APT, Transport, Coeliac disease, MNA, Medical device, Birth control, Esophagus, Disease, Region

The global Smart Pills Technology market is a growing segment in the transportation industry.

Key Points: 
  • The global Smart Pills Technology market is a growing segment in the transportation industry.
  • The global smart pills technology market is expected to grow significantly over the forecast period due to increasing demand for non-invasive diagnostic tools and personalized medicine.
  • Additionally, advancements in wireless communication technologies and the miniaturization of electronic components are also driving the growth of the smart pills technology market.
  • Smart Pills Technology Market is segmented based on the Application, target area, disease, end user, and region.

EQS-News: Immunic to Participate in Scientific and Investor Conferences in July

Retrieved on: 
Thursday, June 29, 2023
Mayo Clinic, Clinic, Beth Israel Deaconess Medical Center, Biotechnology, Regeneration, Virology, Harvard Medical School, Hepatology, Division, Internal medicine, Human, Webcast, Poster, Pharmacology, Coeliac disease, Treatment, Pharmaceutical industry, Dentistry, Gastroenterology, Immune disorder, Medicine

The poster presentation will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • Immunic’s collaboration partner will present a poster and participate in a satellite workshop at this conference in Missoula, Montana.
  • An archived replay of the webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .

Immunic to Participate in Scientific and Investor Conferences in July

Retrieved on: 
Thursday, June 29, 2023
Mayo Clinic, Clinic, Beth Israel Deaconess Medical Center, Biotechnology, Clinical trial, Regeneration, Virology, Harvard Medical School, Hepatology, Division, Internal medicine, Human, Webcast, Poster, Pharmacology, Coeliac disease, Treatment, Pharmaceutical industry, Vaccine, Dentistry, Gastroenterology, Short course immune induction therapy, Medicine

The poster presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • Immunic's collaboration partner will present a poster and participate in a satellite workshop at this conference in Missoula, Montana.
  • An archived replay of the webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .